Shares of Veru Inc. jumped 10.4% to $2.35 after Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $24 price target — citing confidence that interim results next quarter will show enobosarm preserves lean body mass and increases fat loss versus semaglutide alone. The call implies more than 900% upside from current levels, an extraordinary bet on a company that has no revenue, is burning cash, and hinges almost entirely on one mid-stage clinical readout.

  • A $24 Target on a $2 Stock Tells You Everything About the Risk. Oppenheimer reiterated its rating ahead of expected clinical trial results, with the stock having declined roughly 11% over the prior week. The reaffirmation broke that slide, but the chasm between price and target reflects a binary outcome: if the trial succeeds, the drug could tap the booming GLP-1 weight-loss market; if it fails, the stock has little floor beneath it. Out of three analysts covering VERU, one rates it Sell, zero Hold, and two Buy — meaning even Wall Street is split.

  • Novo Nordisk's Backing Is Real, but Limited. Veru signed a June 2026 clinical supply deal under which Novo Nordisk will provide its blockbuster Wegovy for free and gain trial insights plus first negotiation rights on future enobosarm-GLP-1 combination opportunities. That endorsement from the world's largest obesity-drug maker is meaningful, yet Veru retains full global rights to enobosarm, and there is no disclosed upfront or milestone payment structure. Novo risked very little; Veru still carries the financial load.

  • The Cash Runway Is the Real Clock. Cash on hand at June 30, 2026, was $23.9 million , while operating activities consumed $20.6 million in the first nine months of fiscal 2026.

The company is not profitable, acknowledges it needs substantial capital, and estimates its cash is insufficient to fund operations for the next twelve months. A dilutive capital raise before or shortly after the data readout is a near-certainty.

  • The Trial Itself Is the Only Thing That Matters. The Phase 2b study is fully enrolled with 239 patients, and an interim analysis is on track for calendar Q1 2027. The drug is designed to preserve muscle while patients lose weight on GLP-1 drugs — a problem that has plagued the entire weight-loss class, particularly in older adults. Positive data could trigger partnership interest or acquisition talks. Negative data could wipe out most of the stock's remaining value.

For investors, Veru is a textbook high-risk biotech wager: a validated scientific concept, a ticking financial clock, and one dataset that will determine the outcome.